Is Chronic Constipation holding you back?
Chronic Idiopathic Constipation
The ACCEL clinical research study is for adults who are living with chronic idiopathic constipation (CIC), also called functional constipation (FC). If you’ve been struggling with infrequent, difficult, or incomplete bowel movements for more than 3 months, even after trying a high fiber diet or over-the-counter laxatives, you’re not alone. The ACCEL study is designed to evaluate an investigational treatment that may help improve symptoms of chronic constipation.
Study information:
Condition: Chronic Idiopathic Constipation
Location: Las Vegas, Nevada
Duration: Up to 32 weeks
Participation: Up to 10 visits
Compensation: Up to $750
Eligibility:
Age 18 to 80
At least 3 months of functional constipation:
Fewer than 3 bowel movements each week
Excessive straining
Have not been diagnosed with IBS
IBS, IBS-C, IBS-D, or IBS-M
Other study requirements apply.
Participants may receive:
Compensation up to $750
Study support and monitoring by a healthcare team
Diagnostic tests and procedures at no-cost
Access to a new possible therapy for people with functional constipation
Some participants will receive placebo, which will have no effect on their condition.
Get started today.
You are not committed to participate in a study by completing this form. Participation is voluntary, and you may leave at any time if you change your mind.
What is Chronic Idiopathic Constipation?
Constipation means it’s hard to have a bowel movement (poop). With constipation, you may go less than usual, have difficult bowel movements, which may be difficult to pass.
Constipation is common and can happen to anyone, but chronic constipation means your constipation lasts for a long time.
The investigational study medication, tenapanor, is designed to reduce the amount of sodium (salt) absorption that happens in your gastrointestinal (GI) system. By keeping more salt in your GI system, more water is retained there. This increase in water can help soften your bowel movements, resulting in an increase in frequency and making them easier to pass.
Tenapanor is currently approved in the U.S. for adult patients with IBS-C.
Information provided by: https://www.constipationstudy.com/

